ANGPTL4 regulate glutamine metabolism and fatty acid oxidation in nonsmall cell lung cancer cells

Song Xiao1, Wang Nai-Dong2, Yan Jin-Xiang3

  • 1Radiotherapy Department, the First Affiliated Hospital of Hebei North University, Zhangjiakou, China.

Insights

Angiopoietin-like protein 4 (ANGPTL4) promotes cancer growth in non-small cell lung cancer (NSCLC) by increasing glutamine consumption and fatty acid oxidation, not glycolysis. Inhibiting ANGPTL4 may offer a therapeutic strategy for NSCLC.

Area of Science:

  • Oncology
  • Metabolic Regulation
  • Cancer Metabolism

Background:

  • Angiopoietin-like protein 4 (ANGPTL4) is implicated in metabolic diseases and is upregulated in various cancers.
  • The precise role of ANGPTL4 in regulating tumor energy metabolism, particularly in non-small cell lung cancer (NSCLC), requires further elucidation.

Purpose of the Study:

  • To investigate the function of ANGPTL4 in aerobic glycolysis, glutamine consumption, and fatty acid oxidation within NSCLC cells.
  • To identify molecular targets regulated by ANGPTL4 in NSCLC.

Main Methods:

  • Utilized two NSCLC cell lines (A549 and H1299) with ANGPTL4 knockdown.
  • Employed tracer techniques and Seahorse XF technology to assess energy metabolism.
  • Conducted RNA microarrays and utilized specific inhibitors to identify ANGPTL4 targets.

Main Results:

  • ANGPTL4 knockdown inhibited NSCLC proliferation and energy metabolism, specifically impacting glutamine consumption and fatty acid oxidation, with minimal effect on glycolysis.
  • ANGPTL4 knockdown significantly reduced tumor metastasis and energy metabolism in mice.
  • RNA microarray analysis identified glutaminase (GLS) and carnitine palmitoyl transferase 1 (CPT1) as key targets affected by ANGPTL4.

Conclusions:

  • ANGPTL4 promotes NSCLC progression by enhancing glutamine consumption and fatty acid oxidation, thereby accelerating tumor energy metabolism.
  • Targeting ANGPTL4, GLS, and CPT1 simultaneously presents a potential therapeutic strategy for NSCLC treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K